---
input_text: "Long-Term Urinary Copper Excretion on Chelation Therapy in Children with
  Wilson Disease. OBJECTIVES: In Wilson disease (WD), 24-hour urinary copper excretion
  (UCE) is recommended to be used for diagnosis. It may be a useful tool to assess
  the efficacy of treatment during follow-up; however, there are limited data regarding
  the cutoff value of 24-hour UCE during follow-up in children. Therefore, we aim
  to evaluate the clinical use of 24-hour UCE during follow-up in children with WD.
  PATIENTS AND METHODS: Medical records of children diagnosed with WD at Kings' College
  Hospital from 2005 to 2018 were retrospectively reviewed. The UCE, serum copper,
  and ceruloplasmin levels, tested during follow-up, were statistically analyzed.
  RESULTS: Over the median duration of 7 years (range 1.4-14.4), 28 patients (age
  ranged 3.8-17.3 years) had UCE tests during follow-up. Of those, 21 patients had
  at least one 24-hour UCE test and 7 children had only spot UCE tests. In comparison
  with the level of 24-hour UCE collected at the first visit after penicillamine challenge
  test, the median excretion rate was significantly reduced over the follow-up period
  (P < 0.001), from 26.2 to 8.9 mumol/day following 1-2 years of therapy (P = 0.15),
  then reduced significantly to 2.2 mumol/day after 3-4 years (P = 0.009), and 5.6
  mumol/day at >5 years of follow-up (P = 0.003). CONCLUSIONS: Our study suggests
  that within 1 year of treatment, the level of nonceruloplasmin-bound copper concentration
  (NCC) drops to <0.8 mumol/L. In the absence of progressive liver disease or signs
  of copper deficiency, 24-hour UCE decreases to <=8 mumol/day and <6 mumol/day after
  1 and 5 years of treatment, respectively."
raw_completion_output: |-
  primary_disease: Wilson Disease

  medical_actions: 24-hour urinary copper excretion test; Chelation therapy; Penicillamine challenge test

  symptoms: Progressive liver disease; copper deficiency

  chemicals: Penicillamine; Copper; Ceruloplasmin

  action_annotation_relationships: 24-hour urinary copper excretion test TREATS Progressive liver disease IN Wilson Disease; Chelation therapy (with Penicillamine) TREATS copper deficiency IN Wilson Disease; Penicillamine challenge test TREATS copper deficiency IN Wilson Disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Penicillamine challenge test TREATS copper deficiency IN Wilson Disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - 24-hour urinary copper excretion test
    - Chelation therapy
    - Penicillamine challenge test
  symptoms:
    - Progressive liver disease
    - HP:0011967
  chemicals:
    - CHEBI:50868
    - CHEBI:28694
    - Ceruloplasmin
  action_annotation_relationships:
    - subject: <24-hour urinary copper excretion test>
      predicate: <TREATS>
      object: <Progressive liver disease>
      qualifier: <Wilson Disease>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <24-hour urinary copper excretion test>
      object_extension: <Progressive liver disease>
    - subject: Chelation therapy
      predicate: TREATS
      object: HP:0011967
      qualifier: MONDO:0010200
      subject_qualifier: with Penicillamine
      subject_extension: CHEBI:50868
    - subject: challenge test
      predicate: TREATS
      object: HP:0011967
      qualifier: MONDO:0010200
      subject_qualifier: Penicillamine
      subject_extension: CHEBI:50868
      object_extension: copper deficiency
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0001695
    label: Cardiac arrest
  - id: HP:0001685
    label: Myocardial fibrosis
  - id: HP:0001663
    label: Ventricular fibrillation
  - id: CHEBI:28694
    label: Copper
  - id: CHEBI:18248
    label: Iron
  - id: HP:0002910
    label: abnormal liver functions
  - id: HP:0001394
    label: cirrhosis
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:50868
    label: penicillamine
  - id: MAXO:0000016
    label: Cell therapy
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:30703
    label: Tetrathiomolybdate (TTM)
  - id: HP:0006554
    label: acute liver failure
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0009095
    label: zinc therapy
  - id: MAXO:0001298
    label: therapy
  - id: HP:0006579
    label: neonatal jaundice
  - id: HP:0001409
    label: portal hypertension
  - id: HP:0030151
    label: cholangitis
  - id: HP:0002612
    label: congenital hepatic fibrosis
  - id: MONDO:0013282
    label: alpha-1-antitrypsin deficiency
  - id: HP:0001903
    label: anemia
  - id: HP:0001410
    label: liver dysfunction
  - id: CHEBI:39501
    label: trientine
  - id: MAXO:0000070
    label: Hepatic transplantation
  - id: HP:0001399
    label: Hepatic failure
  - id: HP:0004448
    label: fulminant hepatic failure
  - id: HP:0003256
    label: coagulopathy (international normalized ratio >2.0)
  - id: HP:0004445
    label: hepatic encephalopathy (HE)
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:33281
    label: Antibiotics
  - id: MONDO:0100193
    label: End-stage liver disease
  - id: HP:0100626
    label: End-stage liver disease
  - id: HP:0100660
    label: dyskinesia
  - id: HP:0100022
    label: Movement disorders
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: MONDO:0019542
    label: Acute liver failure (ALF)
  - id: CHEBI:27385
    label: CCL4
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0001017
    label: Vaccination
  - id: HP:0001541
    label: Ascites
  - id: HP:0012398
    label: Peripheral edema
  - id: HP:0001260
    label: dysarthria
  - id: HP:0000708
    label: psychiatric disorders
  - id: HP:0200123
    label: chronic hepatitis
  - id: CHEBI:38161
    label: chelators
  - id: MAXO:0000376
    label: liver biopsy
  - id: HP:0001404
    label: hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0001744
    label: Splenomegaly
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: HP:0002172
    label: impaired balance
  - id: HP:0001347
    label: hyperreflexia
  - id: HP:0031843
    label: bradyphrenia
  - id: HP:0002362
    label: shuffling gait
  - id: HP:0001621
    label: hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: pramipexole
  - id: CHEBI:2618
    label: amantadine
  - id: HP:0000093
    label: proteinuria
  - id: CHEBI:231592
    label: zinc salts
  - id: MAXO:0000167
    label: antiepileptic therapy
  - id: CHEBI:9168
    label: rapamycin
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:35623
    label: antiepileptic
  - id: HP:0000083
    label: renal failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0001342
    label: intracerebral hemorrhage
  - id: MAXO:0000533
    label: molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0001298
    label: Encephalopathy
  - id: MAXO:0009070
    label: SPECT
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:166831
    label: copper chelators
  - id: MAXO:0035064
    label: electron microscopic studies
  - id: MAXO:0000139
    label: autopsy
  - id: HP:0006577
    label: macronodular cirrhosis
  - id: CHEBI:8830
    label: rhodanine
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0007263
    label: Spinocerebellar Ataxia
  - id: MAXO:0001610
    label: transcranial magnetic stimulation
  - id: HP:0002015
    label: dysphagia
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0000437
    label: Spinocerebellar degeneration
  - id: CHEBI:2948
    label: Azathioprine
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0031690
    label: opportunistic infections
  - id: HP:0001397
    label: Steatosis
  - id: HP:0001513
    label: Obesity
  - id: HP:0000819
    label: Diabetes
  - id: HP:6000457
    label: Mallory bodies
  - id: HP:0002829
    label: Arthralgia
  - id: CHEBI:9907
    label: Ursodeoxycholic acid
  - id: MONDO:0007027
    label: Non-alcoholic steatohepatitis (NASH)
  - id: MONDO:0006507
    label: Hereditary hemochromatosis (HH)
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (AML)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0004808
    label: Acute Myeloid Leukemia (AML)
  - id: CHEBI:16856
    label: Glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: HP:0001289
    label: Confusion
  - id: CHEBI:46195
    label: Acetaminophen
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: MONDO:0003441
    label: dystonia
  - id: MAXO:0009015
    label: botulinum toxin injection
  - id: MAXO:0000943
    label: deep brain stimulation
  - id: HP:0004305
    label: involuntary movements
  - id: CHEBI:9720
    label: trihexyphenidyl
  - id: CHEBI:35474
    label: minor tranquilizers
  - id: HP:0005268
    label: spontaneous abortion
  - id: HP:0100520
    label: oliguria
  - id: CHEBI:16737
    label: creatinine
  - id: HP:0100543
    label: Cognitive impairment
  - id: HP:0001250
    label: epileptic seizures
  - id: HP:0002315
    label: headache
  - id: CHEBI:6437
    label: levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: MONDO:0004789
    label: Cholangitis
  - id: CHEBI:33234
    label: Vitamin E
  - id: HP:0001953
    label: diabetic ketoacidosis (DKA)
  - id: HP:0001942
    label: metabolic acidosis
  - id: HP:0001946
    label: ketosis
  - id: HP:0003781
    label: Hypersalivation
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0000707
    label: neurologic abnormalities
  - id: CHEBI:16796
    label: Melatonin
  - id: HP:0011967
    label: copper deficiency
